KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non –small-cell lung cancer
ConclusionThe combination of epacadostat plus pembrolizumab and chemotherapy was found to be tolerable in Japanese patients with advanced NSCLC.Trial registrationClinicalTrials.gov, NCT02862457.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Alimta | Cancer | Cancer & Oncology | Chemotherapy | Cytology | Drugs & Pharmacology | Investigational New Drugs | Japan Health | Lung Cancer | Non-Small Cell Lung Cancer | Study | Toxicology